Mapping brain circuits and studying the neural signals that are activated during post-traumatic stress could provide an answer to the generalized fear associated with this disorder. Scientists at the University of California, San Diego have identified a change in the expression of neurotransmitters as an adaptive response that could trigger this effect.
In what represents their first patenting, a researcher from the University of California is seeking protection for non-invasive methods of brain monitoring that use electroencephalography (EEG) to detect new or worsening brain injury in pediatric patients.
Xgene Pharmaceutical Pty Ltd., a subsidiary of Xgene Pharmaceutical Co. Ltd., has received approval in Australia to initiate a phase I trial of the selective TRPM8 blocker XG-2002 (RQ-00434739).
Genzyme Corp. (dba Sanofi Genzyme) has disclosed isoxazolidine compounds acting as receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of Alzheimer’s disease and multiple sclerosis, among others.
Alterations in mitochondrial dynamics are hallmarks of Parkinson’s disease (PD) and other neurodegenerative disorders such as Alzheimer’s disease (AD).
Sangamo Therapeutics Inc. has reported data from nonhuman primate (NHP) studies showing the potential of its proprietary AAV capsid variant, STAC-BBB, as a neurotropic capsid when administered intravenously at clinically relevant doses. STAC-BBB outperformed results for other evaluated neurotropic capsid variants.
Advances in understanding the processes underlying brain neurodegeneration have allowed lots of new treatment and prevention strategies to begin to flourish. Several presentations at the 2024 Alzheimer’s & Parkinson’s Diseases Conference recently held in Lisbon reflect that eyes are now on some individuals who, despite showing pathological signs in their brains, stay cognitively healthy across several endogenous mechanisms of resilience.
Japanese researchers from Chiba University are spearheading new research into Peace of Mind Co. Ltd.’s portable Angel Touch device (AT-04), approved for neurological disorders, to treat endometriosis-related pain.
Agenebio Inc. has identified benzodiazepine derivatives acting as GABA(A) receptor subunits α5β3γ2 (GABRA5) positive allosteric modulators reported to be useful for the treatment of mild cognitive impairment, amyotrophic lateral sclerosis, schizophrenia, post-traumatic stress, autism, substance abuse and dependence, Alzheimer’s disease and Parkinson’s disease, among others.
In a new study, researchers from Harvard Medical School and Regulus Therapeutics Inc. further investigated the role of miR-155 in Alzheimer's disease (AD).